FDA steps up on compounded GLP‑1 drugs: safety first or over‑reach?
Posted by greg208 in Research & News - 2 points, 0 comments.
The FDA has proposed new rules വ്യക്ത limiting compounding facilities from making semaglutide, tirzepatide and liraglutide, the active ingredients behind Ozempic, Wegovy and Mounjaro. The move follows a period of shortage‑driven compounding that left some patients on uncertain quality drugs.
I’m a bit wary of the push. On one hand, the FDA’s point about standardising purity makes sense; I’ve catalysts that crowd around safety when a drug is mass‑produced. On the other hand, restricting compounding could push patients toward non‑regulated outlets, especially in the UK where tele‑health prescriptions are common. The article frames the FDA's action as purely protective, but it glosses over how many patients were actually experiencing problems from compounding – a real concern I’ve heard from friends.
Do you think the FDA should keep these drugs off the compounding list, or would that limit access for those who rely on cheaper, online prescription options?
Community discussion - research and educational context only. Not medical advice.